by Raynovich Rod | Jan 18, 2016 | 2025 Rayno Biopharmaceuticals Portfolio
Valuation Models for Large Cap Biopharma Stocks Can Robust Drug Pipelines Deliver Future EPS Growth? This is a follow-up of our post on 1/8/16 Large Cap Biopharmaceuticals which looks at valuation models and stock performance of selected companies after the...
by Raynovich Rod | Jan 8, 2016 | 2025 Rayno Biopharmaceuticals Portfolio, Biopharmaceuticals
Large Cap Biopharmaceutical Stock Valuations After Correction We previously summarized the Rayno Mid and Small Cap Portfolios for 2015, a good year despite the correction. With this post we summarized selected Sales and Earnings metrics (Source finviz.com) of...
by Raynovich Rod | Jan 3, 2016 | 2025 Rayno Biopharmaceuticals Portfolio, Biopharmaceuticals
Biotech Winners 2015: Rayno Mid-Cap Performance Rayno Biopharmaceutical Portfolios beat the bellwether IBB in 2015 . We previously reviewed the Rayno Small Cap Portfolio which was up 38.1% in Q4 2015 and the Mid-Caps also beat despite a big loss by Clovis Oncology...
by Raynovich Rod | Dec 29, 2015 | 2025 Rayno Biopharmaceuticals Portfolio
Rayno Small Cap Biopharmaceuticals -Strong Rally, Good Momentum with Overall Market We recommended three new small caps at the October Bioinvestor Forum: Curis (CRIS) Geron (GERN) and Ocera Therapeutics. This BIO sponsored forum offers the best window on emerging...
by Raynovich Rod | Dec 28, 2015 | 2025 Rayno Biopharmaceuticals Portfolio, Biopharmaceuticals
Biopharma Rally On Hold When you read the Transfs online trading guide, you will begin to understand that trading can be a volatile investment. There will be amazing days, weeks, or months where rates are perfect for you but there will also be days, weeks, or months...
by Raynovich Rod | Dec 16, 2015 | 2025 Rayno Biopharmaceuticals Portfolio, Biopharmaceuticals
Update after close 12/16…IBB up 2.25%, XBI up 4.45% Rayno Life Science Big Movers Rayno Biopharma ABBV up 2.2%,ALKS up 8.12%, BIIB up 3.52%, ARRY up 20.63 %, CRIS up 6.27%, FCSC up 5%, GERN up 4.42%,RXDX up 2.92% and SGEN up 4.93%. Rayno Dx and Tools ABAX up...
by Raynovich Rod | Dec 1, 2015 | 2025 Rayno Biopharmaceuticals Portfolio, Biopharmaceuticals
Look for Growth in Emerging Small Cap Drug Stocks Many stocks were in the red Monday with healthcare a lagging sector down 1%. Many investors await economic data later this week and the mid-December meeting for the FED. Biotech stocks are also weak today with the...
by Raynovich Rod | Nov 19, 2015 | 2024 Rayno Tools and Diagnostics Portfolio, 2024-25 Life Science Portfolios, 2025 Rayno Biopharmaceuticals Portfolio
Update-1 Rayno Recap for week of 11/20/15 IBB up 3.04%, XBI up 1.92%, XLV up 2.82% Notable Small Cap Winners Curis (CRIS) up 4.13%, Fibrocell Sciences (FCSC) up 3.42%, Geron (GERN) up 4.82%, Ignyta (RXDX) up 37.39%, and Ocera Therapeutics (OCRX) up 5.31%. Notable...
by Raynovich Rod | Oct 13, 2015 | 2025 Rayno Biopharmaceuticals Portfolio, Biopharmaceuticals, Life Science ETF's and Mutual Funds
10/15 After the Close… XBI Up 7.26%…Green Screen…MOmentum is back Biotech stocks soared today in a broad rally showing a good appetite especially for small and mid-cap stocks. This could be a counter-trend rally in a biotech bear market but there is...
by Raynovich Rod | Jul 14, 2015 | 2025 Rayno Biopharmaceuticals Portfolio
Rayno Top Winners YTD 10/12/15 Fibrocell Science (FCSC) up 69% Clovis Oncology (CLVS) up 61.6% Regeneron (REGN) up 28.4% Seattle Genetics (SGEN) up 21.3% Gilead Sciences (GILD) up 5.6% —— Rayno Top Losers YTD Biogen Idec (BIIB) down 21.5%….down again...
